Logotipo del repositorio
Logotipo del repositorio
 

Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries

Vista sencilla de ítem
datacite.rightshttp://purl.org/coar/access_right/c_abf2
dc.contributor.authorBolla, Eleana
dc.contributor.authorSemb, Anne Grete
dc.contributor.authorKerola, Anne M.
dc.contributor.authorIkdahl, Eirik
dc.contributor.authorPetri, Michelle
dc.contributor.authorPons-Estel, Guillermo J.
dc.contributor.authorKarpouzas, George A.
dc.contributor.authorSfikakis, Petros P.
dc.contributor.authorQuintana, Rosana
dc.contributor.authorPrasanna Misra, Durga
dc.contributor.authorFerreira Borba, Eduardo
dc.contributor.authorGarcia-de la Torre, Ignacio
dc.contributor.authorPopkova, Tatiana V.
dc.contributor.authorArtim-Esen, Bahar
dc.contributor.authorTroldborg, Anne
dc.contributor.authorFragoso-Loyo, Hilda
dc.contributor.authorAjeganova, Sofia
dc.contributor.authorYazici, Ayten
dc.contributor.authorAroca-Martinez, Gustavo
dc.contributor.authorDireskeneli, Haner
dc.contributor.authorUgarte-Gil, Manuel F.
dc.contributor.authorMosca, Marta
dc.contributor.authorGoyal, Mohit
dc.contributor.authorSvenungsson, Elisabet
dc.contributor.authorMacieira, Carla
dc.contributor.authorHoi, Alberta
dc.contributor.authorLerang, Karoline
dc.contributor.authorCostedoat-Chalumeau, Nathalie
dc.contributor.authorTincani, Angela
dc.contributor.authorMirrakhimov, Erkin
dc.contributor.authorAcosta Colman, Isabel
dc.contributor.authorDanza, Alvaro
dc.contributor.authorMassardo, Loreto
dc.contributor.authorBlagojevic, Jelena
dc.contributor.authorYılmaz, Neslihan
dc.contributor.authorTegzová, Dana
dc.contributor.authorYavuz, Sule
dc.contributor.authorKorkmaz, Cengiz
dc.contributor.authorHachulla, Eric
dc.contributor.authorMoreno Alvarez, Mario J.
dc.contributor.authorMuñoz-Louis, Roberto
dc.contributor.authorPantazis, Nikos
dc.contributor.authorTektonidou, Maria G.
dc.contributor.authorbehalf of the SURF-SLE and APS
dc.date.accessioned2024-07-29T22:40:23Z
dc.date.available2024-07-29T22:40:23Z
dc.date.issued2024
dc.description.abstractBackground Systemic lupus erythematosus (SLE) is characterised by increased cardiovascular morbidity and mortality risk. We aimed to examine the prevalence of traditional cardiovascular risk factors and their control in an international survey of patients with systemic lupus erythematosus. Methods In this multicentre, cross-sectional study, cardiovascular risk factor data from medical files of adult patients (aged ≥18) with SLE followed between Jan 1, 2015, and Jan 1, 2020, were collected from 24 countries, across five continents. We assessed the prevalence and target attainment of cardiovascular risk factors and examined potential differences by country income level and antiphospholipid syndrome coexistence. We used the Systemic Coronary Risk Evaluation algorithm for cardiovascular risk estimation, and the European Society of Cardiology guidelines for assessing cardiovascular risk factor target attainment. People with lived experience were not involved in the research or writing process. Findings 3401 patients with SLE were included in the study. The median age was 43·0 years (IQR 33–54), 3047 (89·7%) of 3396 patients were women, 349 (10.3%) were men, and 1629 (48·1%) of 3390 were White. 556 (20·7%) of 2681 patients had concomitant antiphospholipid syndrome. We found a high cardiovascular risk factor prevalence (hypertension 1210 [35·6%] of 3398 patients, obesity 751 [23·7%] of 3169 patients, and hyperlipidaemia 650 [19·8%] of 3279 patients), and suboptimal control of modifiable cardiovascular risk factors (blood pressure [target of <130/80 mm Hg], BMI, and lipids) in the entire SLE group. Higher prevalence of cardiovascular risk factors but a better blood pressure (target of <130/80 mm Hg; 54·9% [1170 of 2132 patients] vs 46·8% [519 of 1109 patients]; p<0·0001), and lipid control (75·0% [895 of 1194 patients] vs 51·4% [386 of 751 patients], p<0·0001 for high-density lipoprotein [HDL]; 66·4% [769 of 1158 patients] vs 60·8% [453 of 745 patients], p=0·013 for non-HDL; 80·9% [1017 of 1257 patients] vs 61·4% [486 of 792 patients], p<0·0001 for triglycerides]) was observed in patients from high-income versus those from middle-income countries. Patients with SLE with antiphospholipid syndrome had a higher prevalence of modifiable cardiovascular risk factors, and significantly lower attainment of BMI and lipid targets (for low-density lipoprotein and non-HDL) than patients with SLE without antiphospholipid syndrome. Interpretation High prevalence and inadequate cardiovascular risk factor control were observed in a large multicentre and multiethnic SLE cohort, especially among patients from middle-income compared with high-income countries and among those with coexistent antiphospholipid syndrome. Increased awareness of cardiovascular disease risk in SLE, especially in the above subgroups, is urgently warranted.eng
dc.format.mimetypepdf
dc.identifier.citationEleana Bolla, Anne Grete Semb, Anne M Kerola, Eirik Ikdahl, Michelle Petri, Guillermo J Pons-Estel, George A Karpouzas, Petros P Sfikakis, Rosana Quintana, Durga Prasanna Misra, Eduardo Ferreira Borba, Ignacio Garcia-de la Torre, Tatiana V Popkova, Bahar Artim-Esen, Anne Troldborg, Hilda Fragoso-Loyo, Sofia Ajeganova, Ayten Yazici, Gustavo Aroca-Martinez, Haner Direskeneli, Manuel F Ugarte-Gil, Marta Mosca, Mohit Goyal, Elisabet Svenungsson, Carla Macieira, Alberta Hoi, Karoline Lerang, Nathalie Costedoat-Chalumeau, Angela Tincani, Erkin Mirrakhimov, Isabel Acosta Colman, Alvaro Danza, Loreto Massardo, Jelena Blagojevic, Neslihan Yılmaz, Dana Tegzová, Sule Yavuz, Cengiz Korkmaz, Eric Hachulla, Mario J Moreno Alvarez, Roberto Muñoz-Louis, Nikos Pantazis, Maria G Tektonidou, Veronica Bellomio, Ilaria Cavazzana, Nikita Khmelinskii, Odirlei Andre Monticielo, Margarita Portela Hernández, Miguel Angel Saavedra Salinas, Marina Scolnik, Ana Carolina Silva Montandon, Esin Yilmaz, Dina Zucchi, Prevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countries, The Lancet Rheumatology, Volume 6, Issue 7, 2024, Pages e447-e459, ISSN 2665-9913, https://doi.org/10.1016/S2665-9913(24)00090-0.eng
dc.identifier.doidoi.org/10.1016/ S2665-9913(24)00090-0
dc.identifier.issn26659913 (En línea)
dc.identifier.urihttps://hdl.handle.net/20.500.12442/14939
dc.identifier.urlhttps://www.sciencedirect.com/science/article/abs/pii/S2665991324000900?via%3Dihub
dc.language.isoeng
dc.publisherElseviereng
dc.rightsAttribution-NonCommercial-NoDerivs 3.0 United Stateseng
dc.rights.accessrightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/3.0/us/
dc.sourceThe Lancet Reumatologíaeng
dc.sourceVol. 6 No. 7, (2024)
dc.titlePrevalence and target attainment of traditional cardiovascular risk factors in patients with systemic lupus erythematosus: a cross-sectional study including 3401 individuals from 24 countrieseng
dc.type.driverinfo:eu-repo/semantics/article
dc.type.spaArtículo científicospa
dcterms.referencesYazdany J, Pooley N, Langham J, et al. Systemic lupus erythematosus; stroke and myocardial infarction risk: a systematic review and meta-analysis. RMD Open 2020; 6: e001247.eng
dcterms.referencesTektonidou MG, Lewandowski LB, Hu J, Dasgupta A, Ward MM. Survival in adults and children with systemic lupus erythematosus: a systematic review and Bayesian meta-analysis of studies from 1950 to 2016. Ann Rheum Dis 2017; 76: 2009–16.eng
dcterms.referencesSchoenfeld SR, Kasturi S, Costenbader KH. The epidemiology of atherosclerotic cardiovascular disease among patients with SLE: a systematic review. Semin Arthritis Rheum 2013; 43: 77–95.eng
dcterms.referencesFarina N, Abdulsalam R, McDonnell T, et al. Antiphospholipid antibody positivity in early systemic lupus erythematosus is associated with subsequent vascular events. Rheumatology 2023; 62: 2252–56.eng
dcterms.referencesDrosos GC, Vedder D, Houben E, et al. EULAR recommendations for cardiovascular risk management in rheumatic and musculoskeletal diseases, including systemic lupus erythematosus and antiphospholipid syndrome. Ann Rheum Dis 2022; 81: 768–79.eng
dcterms.referencesPapazoglou N, Kravvariti E, Konstantonis G, Sfikakis PP, Tektonidou MG. The impact of traditional cardiovascular risk factor control on 7-year follow-up atherosclerosis progression in systemic lupus erythematosus. Rheumatology 2024; 63: 50–57.eng
dcterms.referencesChow CK, Teo KK, Rangarajan S, et al. Prevalence, awareness, treatment, and control of hypertension in rural and urban communities in high-, middle-, and low-income countries. JAMA 2013; 310: 959–68.eng
dcterms.referencesMaynard JW, Fang H, Petri M. Low socioeconomic status is associated with cardiovascular risk factors and outcomes in systemic lupus erythematosus. J Rheumatol 2012; 39: 777–83.eng
dcterms.referencesRollefstad S, Ikdahl E, Wibetoe G, et al. An international audit of the management of dyslipidaemia and hypertension in patients with rheumatoid arthritis: results from 19 countries. Eur Heart J Cardiovasc Pharmacother 2022; 8: 539–48.eng
dcterms.referencesPetri M, Orbai AM, Alarcón GS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheum 2012; 64: 2677–86.eng
dcterms.referencesMiyakis S, Lockshin MD, Atsumi T, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295–306.eng
dcterms.referencesPiepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). Eur Heart J 2016; 37: 2315–81.eng
dcterms.referencesBruce IN, Urowitz MB, Gladman DD, Ibañez D, Steiner G. Risk factors for coronary heart disease in women with systemic lupus erythematosus: the Toronto Risk Factor Study. Arthritis Rheum 2003; 48: 3159–67.eng
dcterms.referencesUrowitz MB, Gladman D, Ibañez D, et al. Clinical manifestations and coronary artery disease risk factors at diagnosis of systemic lupus erythematosus: data from an international inception cohort. Lupus 2007; 16: 731–35.eng
dcterms.referencesDagenais GR, Leong DP, Rangarajan S, et al. Variations in common diseases, hospital admissions, and deaths in middle-aged adults in 21 countries from five continents (PURE): a prospective cohort study. Lancet 2020; 395: 785–94.eng
dcterms.referencesUrowitz MB, Gladman DD, Anderson NM, et al. Cardiovascular events prior to or early after diagnosis of systemic lupus erythematosus in the systemic lupus international collaborating clinics cohort. Lupus Sci Med 2016; 3: e000143.eng
dcterms.referencesUrowitz MB, Su J, Gladman DD. Atherosclerotic vascular events in systemic lupus erythematosus: an evolving story. J Rheumatol 2020; 47: 66–71.eng
dcterms.referencesSaito M, Yajima N, Yanai R, et al. Prevalence and treatment conditions for hypertension and dyslipidaemia complicated with systemic lupus erythematosus: a multi-centre cross-sectional study. Lupus 2021; 30: 1146–53.eng
dcterms.referencesTselios K, Gladman DD, Su J, Urowitz M. Impact of the new American College of Cardiology/American Heart Association definition of hypertension on atherosclerotic vascular events in systemic lupus erythematosus. Ann Rheum Dis 2020; 79: 612–17.eng
dcterms.referencesStojan G, Magder LS, Petri M. Blood pressure variability and agerelated blood pressure patterns in systemic lupus erythematosus. J Rheumatol 2020; 47: 387–93.eng
dcterms.referencesWilliams B, Mancia G, Spiering W, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Eur Heart J 2018; 39: 3021–104eng
dcterms.referencesWhelton PK, Carey RM, Aronow WS, et al. 2017 ACC/AHA/AAPA/ ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults: executive summary: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. Hypertension 2018; 71: 1269–324.eng
dcterms.referencesMach F, Baigent C, Catapano AL, et al. 2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. Eur Heart J 2020; 41: 111–88.eng
dcterms.referencesGrundy SM, Stone NJ, Bailey AL, et al. AHA/ACC/AACVPR/ AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines. J Am Coll Cardiol 2019; 73: 3168–3209eng
dcterms.referencesYu HH, Chen PC, Yang YH, et al. Statin reduces mortality and morbidity in systemic lupus erythematosus patients with hyperlipidemia: a nationwide population-based cohort study. Atherosclerosis 2015; 243: 11–18.eng
dcterms.referencesTaddei C, Zhou B, Bixby H, et al. Repositioning of the global epicentre of non-optimal cholesterol. Nature 2020; 582: 73–77.eng
dcterms.referencesTektonidou MG. Cardiovascular disease risk in antiphospholipid syndrome: thrombo-inflammation and atherothrombosis. J Autoimmun 2022; 128: 102813.eng
dcterms.referencesBolla E, Tentolouris N, Sfikakis PP, Tektonidou MG. Metabolic syndrome in antiphospholipid syndrome versus rheumatoid arthritis and diabetes mellitus: association with arterial thrombosis, cardiovascular risk biomarkers, physical activity, and coronary atherosclerotic plaques. Front Immunol 2023; 13: 1077166.eng
dcterms.referencesBolla E, Tentolouris N, Sfikakis PP, Tektonidou MG. Cardiovascular risk management in antiphospholipid syndrome: trends over time and comparison with rheumatoid arthritis and diabetes mellitus. Lupus Sci Med 2021; 8: e000579.eng
dcterms.referencesRiancho-Zarrabeitia L, Martínez-Taboada V, Rúa-Figueroa I, et al. Antiphospholipid syndrome (APS) in patients with systemic lupus erythematosus (SLE) implies a more severe disease with more damage accrual and higher mortality. Lupus 2020; 29: 1556–65.eng
oaire.versioninfo:eu-repo/semantics/publishedVersion

Archivos

Bloque de licencias
Mostrando 1 - 1 de 1
No hay miniatura disponible
Nombre:
license.txt
Tamaño:
381 B
Formato:
Item-specific license agreed upon to submission
Descripción:
Descargar

Colecciones

Artículos

Universidad Simón Bolívar: Todos los derechos reservados / Sistema de biblioteca